News on research and diagnostics for metabolic disorders and metabolic diseases.
The FDA cleared the system, comprising a blood collection device and associated test to measure long-term glucose levels in patients with diabetes.
The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping.
While results are preliminary, the test could potentially be used in lieu of a liver biopsy.
The collaboration aims at automating the processing of up to 96 liquid biopsy samples at one time using Enable Bio's (ADAP) technology for immunoassays.
The test uses machine learning algorithms to assess predictive biomarkers and electronic health record information to identify progressive kidney disease.
